RGBP · XBRL financial data
Regen BioPharma financial statements, every quarter
The same tables from 13 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters (RGBP's year ends in late September)
| In millions of dollars | Jun 30, 2023 | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Sep 30, 2025 | †Dec 31, 2025 | †Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0* | 0 | 0 | 0 | — | — | — | — | — | — | — |
| Revenue from contracts with customers | 0 | year only | 0 | 0 | 0 | 0* | 0 | 0 | 0* | 0 | 0 | 0 |
| Research and development | 0 | 0* | 0 | 0 | 0 | 0* | 0 | 0 | 0* | 0 | 0 | 0 |
| General and administrative | 0 | 0* | 0 | 0 | 0 | 0* | 0 | 0 | 0* | 0 | 0 | 0 |
| Total operating expenses | — | year only | 0 | 0 | 0 | 0* | 0 | 0 | 0* | 1 | 0 | 0 |
| Operating income (loss) | (0) | (0)* | (0) | (0) | (0) | (0)* | (0) | (0) | (0)* | (1) | (0) | 0 |
| Interest expense | 0 | 0* | 0 | 0 | 0 | 0* | 0 | 0 | 0* | 0 | 0 | 0 |
| Income tax expense (benefit) | — | — | — | — | — | year only | 0 | 0 | 0* | 0 | 0 | 0 |
| Net income (loss) | (0) | (0)* | (0) | (0) | (0) | (0)* | (1) | (0) | (1)* | (1) | 1 | (1) |
| Earnings per share, basic USD per share | (0.03) | — | (0.10) | (0.03) | (0.03) | (0.01)* | (0.13) | 0.00 | — | (0.01) | 0.00 | 0.00 |
| Earnings per share, diluted USD per share | (0.03) | — | (0.10) | (0.03) | (0.03) | (0.01)* | (0.13) | 0.00 | — | (0.01) | 0.00 | 0.00 |
| Weighted average shares, basic millions of shares | 3 | — | 4 | 4 | 4 | 5* | 4 | 22 | — | 100 | 185 | 616 |
| Weighted average shares, diluted millions of shares | 3 | — | 4 | 4 | 4 | 5* | 4 | 22 | — | 100 | 185 | 616 |
- † Share count changed about 4x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 4x in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal quarters (RGBP's year ends in late September)
| In millions of dollars | Jun 30, 2023 | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Sep 30, 2025 | †Dec 31, 2025 | †Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accrued liabilities | — | 2 | — | — | — | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Total current liabilities | 5 | 5 | 5 | 5 | 5 | 5 | 6 | 6 | 7 | 7 | 6 | 6 |
| Total liabilities | 5 | 5 | 5 | 5 | 5 | 5 | 6 | 6 | 7 | 7 | 6 | 6 |
| Accumulated deficit | (19) | (20) | (20) | (20) | (20) | (20) | (21) | (21) | (22) | (23) | (22) | (22) |
| Total stockholders' equity | (5) | (5) | (5) | (5) | (5) | (5) | (6) | (6) | (6) | (7) | (5) | (6) |
| Total liabilities and equity | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Common shares outstanding (cover page) millions of shares | 3 | 4 | 4 | 4 | 5 | 22 | 22 | 22 | 32 | 129 | 512 | 1,675 |
- † Share count changed about 4x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 4x in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal quarters (RGBP's year ends in late September)
| In millions of dollars | Jun 30, 2023 | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Sep 30, 2025 | †Dec 31, 2025 | †Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (loss) | (0) | (0)* | (0) | (0) | (0) | (0)* | (1) | (0) | (1)* | (1) | 1 | (1) |
| Stock-based compensation | — | 0* | — | — | — | 0* | — | — | — | — | — | — |
| Net cash from operating activities | (0)* | (0)* | (0) | (0)* | (0)* | (0)* | (0) | (0)* | (0)* | (0) | (0)* | (0)* |
| Proceeds from issuing common stock | — | — | 0 | 0* | 0* | 0* | — | — | year only | 0 | 0* | 0* |
| Net cash from financing activities | 0* | 0* | 0 | 0* | 0* | 0* | 0 | 0* | 0* | 0 | 0* | 0* |
| Net change in cash | — | year only | 0 | (0)* | (0)* | (0)* | (0) | 0* | 0* | (0) | (0)* | (0)* |
- † Share count changed about 4x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 4x in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Regen BioPharma | 0 | 0.1 | (0)* | 1.7B | 0.0 quarters | 10-QJun 30, 2026 |
| Twinlab Consolidated Holdings | 0 | not reported | (0.9)* | 259.1M | 0.0 quarters | 10-KDec 31, 2024 |
| Zivo Bioscience | 0.1 | 0.1 | (0.3)* | 3.9M | 0.2 quarters | 10-QSep 30, 2025 |
| Evofem Biosciences | 0.3 | 2.6 | (3.1)* | 132.5M | 0.1 quarters | 10-QJun 30, 2026 |
| Hepion Pharmaceuticals | 1.6 | not reported | (1.4)* | 90.2M | 1.2 quarters | 10-QJun 30, 2026 |
| One World Products | 0.2 | 0 | (0.1)* | 120.1M | 1.2 quarters | 10-QSep 30, 2025 |
| China Foods Holdings | 0 | 0 | (0.1)* | 20.3M | 0.2 quarters | 10-QJun 30, 2026 |
| Mosaic ImmunoEngineering | 0 | not reported | (0)* | 7.2M | 0.6 quarters | 10-QJun 30, 2026 |
| Agentix | 0 | not reported | (0) | 40.1M | 0.0 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.